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Abstract
We treated 26 hypothyroid women – 11 with autoimmune thyroiditis and 15 who had been treated for thyroid
cancer – with their usual dose of thyroxine (T
%
) or with a regimen in which 50 µg of T
%
had been replaced by
12.5 µg of triiodothyronine (T
$
). Patients were first randomly assigned to one regimen for 5 wk and then to
a second regimen for an additional 5 wk. The substitution of T
$
for a portion of T
%
caused expected changes
in concentrations of thyroid hormones and thyroid-stimulating hormone (TSH). After combined hormone
treatment there were clear improvements in both cognition and mood, the latter changes being greater. The
patients who had been treated for thyroid cancer showed more mental improvement than the women with
autoimmune thyroiditis, perhaps because they were more dependent on exogenous hormone. Some mood
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Introduction
In a previous report (Bunevicius et al., 1999) our group
described the results of treating 33 hypothyroid patients
with thyroxine (T
%
) alone or with a reduced amount of T
%
combined with a small amount of triiodothyronine (T
$
).
The two treatment programmes exerted about equal
metabolic effects and produced only expected biochemical
effects, with one exception, combined hormone treatment
increased the concentration of sex hormone-binding
globulin (SH-BG) from low normal to high normal. Many
improvements in psychological function occurred after
combined treatment, and in the present report we have
focused in detail on these changes. We have set aside
metabolic and biochemical effects except as the latter
correlate with psychological effects. To achieve these
ends we have purified the sample, deleting from con-
sideration the data that pertain to the 2 men in the larger
sample and to the 4 women who had substantial test
scores for depression. Another woman was found to have
had a high TSH concentration (12.5 µU}ml) at baseline,
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probably due to inadequately treated autoimmune thy-
roiditis. Data pertaining to her were also deleted.
The remaining patients, who are the subject of the
present report, are 26 women, 11 of whom had auto-
immune thyroiditis (AT) and 15 of whom had been
treated with thyroidectomy for thyroid cancer (TC). The
scrutiny and comparison of these two groups is of interest
because AT is a common disease (Tunbridge et al., 1977)
and because TC is increasingly common, at least in parts
of the world where large numbers of people have been
accidentally exposed to radioactive iodine (Kazakov et al.,
1992). Thus, many patients, the majority of whom are
women, require thyroid hormone replacement.




. It is the
only source of T
%
, secreting about 100 µg}d. It also
secretes at least 6 µg}d of T
$
, approx. 24 µg more
coming from deiodination of T
%
by tissues, including brain
(Pilo et al., 1990). It is conventional to provide re-
placement treatment with T
%
alone, in the belief that each
tissue will make sufficient quantities of T
$
(the more
potent hormone) for its own needs. Nevertheless, it has
long been noted that after treatment with T
%
alone not all
patients are entirely well (Taylor et al., 1970). Moreover,
not all tissues are equally able to perform deiodination
(Visser et al., 1982), and the deiodinase in the brain is
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Methods
Patients
Patients were invited to participate if they fulfilled the
following criteria : (i) attended the Institute of Endo-
crinology of the Kaunas Medical University in Kaunas,
Lithuania, (ii) had AT or had been treated for TC with
total thyroidectomy, (iii) were totally or near totally
dependent on exogenous T
%
, (iv) had no other significant
illness, and (v) gave written, informed consent. They were
not selected because they had more than usual complaints.
The initial characteristics of the two diagnostic groups are
shown in Table 1.
Study design
Each patient took her usual dose of T
%
up to and
including the first day of the study. On this day each was
assigned, according to a prearranged randomized sched-
ule, to receive T
%




for 5 wk. After 5 wk the second treatment was given.





was given in usual tablet form except that 50 µg of
T
%
was contained in a capsule. Other capsules of identical
appearance contained 12.5 µg of T
$
. If a patient, for
example, had been treated with 150 µg}d of T
%
, she was
instructed to take 100 µg of the usual T
%
tablets plus one
capsule. Patients took medications once daily, half an hour
before breakfast.
At the end of the first 5-wk period each patient was
given another batch of tablets and capsules. Only the
pharmacist knew which capsules had been dispensed.
Patients, when asked at the end of each treatment period,
said that they had taken their medications as instructed.
Evaluations
Patients were systematically studied on the last day of the
two treatment periods. Having omitted breakfast but
having taken their thyroid hormone about 2 h earlier, they
reported to the clinic at 09 :00 hours. Blood was drawn for
measurement of biochemical variables. Assessments were
made of cognitive function and psychological state, each
patient having the same examiner for whatever variable
was being measured. The examiners were ignorant of the
patients’ treatment assignments.
Biochemical measurements
Serum samples were frozen so that the samples from all
patients could be analysed at the same time for a given
variable. TSH was measured by immunoradiometric assay
with kits obtained from Orion Diagnostica (Espoo,







were measured with radio-
immunoassay kits (Orion Diagnostica). Intra-assay vari-
ation was between 3 and 6 %.
Psychological measurements
Cognitive functioning was measured by use of three tests :
the Digit Symbol test (Wechsler, 1981), the Digit Span
test of the Wechsler Adult Intelligence Scale (Wechsler,
1981), and the Visual Scanning test (Weintraub and
Mesulam, 1985). In the Digit Symbol test a key is shown
that pairs each of the digits 1–9 with a nonsense symbol.
Below are rows of pairs of squares ; the upper square
contains a number, the lower square is blank. Using the
key, the subject is allowed 90 s to complete each pair of
squares, entering the appropriate symbol. The raw score
consists of the number of correct entries completed in 90 s
or until completion of the third row, whichever occurs
first. The score indicates psychomotor performance.
Without using the key, the subject then attempts to recall
which symbol matched each number. The number of pairs
correctly recalled indicates incidental learning. Then the
subject copies 70 symbols. The less time required for
completion, the greater the subject’s psychomotor speed.
In the first part of the Digit Span test the subject is
required to repeat spoken numbers with increasing
numbers of digits ; this indicates immediate auditory
attention. The second part of the test requires the subject
to repeat the numbers in reverse order, indicating mental
flexibility.
The Visual Scanning test measures distractibility and
visual inattentiveness. First the subject is shown a target
symbol, and is then presented with a paper on which is
displayed a matrix of symbols containing 60 copies of the
target. The patient circles all the target symbols that she
can find. The time needed to complete the test, omissions,
and errors are scored.
Three mood scales were completed by each patient :
the Beck Depression Inventory (BDI) (Beck et al., 1961),
the Spielberger State-Trait Anxiety Inventory (SSTAI)
(Spielberger et al., 1983), and the Profile of Mood States
(POMS) (McNair et al., 1992). The BDI is a self-rating
scale consisting of 21 items. Scores of 10 or less indicate
normal mood variation while scores of 11 or more reflect
increasing degrees of depression. The SSTAI, also a self-
rating scale, consists of 20 items. Scores below 50 are
normal. The POMS measures affective states. The subject
responds to 65 items, each pertaining to an aspect of
subjective state, on a scale from 0 to 4. Scores for
combinations of items are added, yielding values for six
aspects of mood and a global score.
Eight visual analogue scales provided detailed ratings
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phrases, such as ‘ sad as possible ’ and ‘happy as possible ’
at either end of a 100 mm line. The patient marks the
point on each line best corresponding to her state at that
time.
Statistical analysis
Paired t tests were used to compare paired data from the
two treatment periods. Non-paired t tests were used to







Age (yr) 45.7³11.4 46.4³9.5
Thyroxine dose (µg}d) 159³54 197³53
Thyroxine duration (months) 95³99 63³58
Thyrotropin (µU}ml) 1.75³2.10* 0.09³0.11




Free thyroxine (ng}dl) 1.8³0.6 2.2³0.6
To convert values for serum-free T
%
to picomoles per litre
multiply by 12.87.
* p¯ 0.007, unpaired t test, autoimmune thyroiditis vs.
thyroid cancer.
Table 2. Biochemical findings in serum after treatment with thyroxine (T
%
) and after













Autoimmune thyroiditis (n¯ 11)
Thyrotropin (µU}ml) 0.79³1.67 0.71³1.41 ns






(ng}dl) 2.04³0.55 1.62³0.54 0.02
Total T
%
(µg}dl) 14.6³2.8 10.1³2.6 0.001
Total T
$
(ng}dl) 110³39 131³43 0.007
Thyroid cancer (n¯ 15)
Thyrotropin (µU}ml) 0.04³0.03 0.09³0.07 ns






(ng}dl) 2.50³0.74 1.97³0.54 ! 0.001
Total T
%
(µg}dl) 16.6³3.0 12.9³2.7 ! 0.001
Total T
$
(ng}dl) 87³36 107³41 0.004
To convert values for serum total and free T
%
to nanomoles per litre and picomoles
per litre, respectively, multiply by 12.87. To convert values for serum T
$
to
nanomoles per litre, multiply by 0.015.
compare values in subgroups of patients. Pearson product-
moment correlation coefficient was used to examine
relationships among selected measurements (Wilkinson et
al., 1992). Probability values were based on two-sided
analyses of test results. All p values greater than 0.05 were
regarded as non-significant. Absolute values are expressed
as mean³standard deviation.
Results
Table 1 shows that the patients in the two diagnostic
groups were about the same age. The women with TC
had not taken T
%
as long as had the women with AT but
had been prescribed larger doses to suppress whatever
residual thyroid tissue they might have had. Probably, as
a consequence of these larger doses, their T
%
concen-
trations were greater and their TSH concentrations were
smaller.
Table 2 shows that the substitution of 12.5 µg of T
$
for
50 µg of T
%
caused biochemical changes that were mostly
expected. In both diagnostic groups the concentrations
of free T
%
and of total T
%
were diminished while the
concentration of total T
$
was increased. The concentration
of TSH was slightly diminished in the AT group while it
was slightly increased in the TC group. Neither of these
two effects was statistically significant, suggesting that
the two treatments exerted about equal metabolic effects.
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Table 3. Cognitive findings after treatment with thyroxine (T
%
) alone and after













Autoimmune thyroiditis (n¯ 11)
Digit Symbol test
Pairs recalled correctly 5.3³3.1 5.4³2.5 ns
Time (s) 143³43 142³39 ns
Raw score 47³14 45³13 ns
Digit Span test
Backward recall 5.3³1.6 5.8³1.6 ns
Forward recall 7.6³2.7 6.5³1.5 ns
Visual Scanning test
Time (s) 81³16 75³16 ns
Total correct 59³1 59³1 ns
Errors 1.3³1.1 1.2³1.0 ns
Thyroid cancer (n¯ 15)
Digit Symbol test
Pairs correctly recalled 5.3³2.1 6.9³1.7 0.02
Time (s) 123³20 124³30 ns
Raw score 50³10 51³10 ns
Digit Span test
Backward recall 6.0³1.4 6.2³0.9 ns
Forward recall 6.5³1.3 7.3³2.0 ns
Visual Scanning test
Time (s) 76³24 69³20 0.02
Total correct 58³2 59³1 ns
Errors 1.8³1.7 1.3³1.5 ns
(after combined hormone treatment) the standard de-
viation was large, indicating that for both diagnostic
groups some patients experienced increases while others
experienced decreases.
Table 3 shows that in the women with AT the two
hormone treatments exerted about equal effects on
measures of cognition. In the women with TC, on the
other hand, statistically significant improvement occurred
in ‘numbers of pairs correctly recalled ’ (Visual Scanning
test) and in ‘ time needed to perform’ (Visual Scanning
test).
Table 4 shows that in neither diagnostic group did the
two treatments exert significantly different effects on
either the BDI or the SSTAI.
Clear difference did occur on the POMS. In the AT
group, combined treatment tended to produce benefits on
5 of the 7 scales, though none of these tendencies was
statistically significant. (Unlike the other subscales, the
vigour–activity subscale indicates improvement when the
score is increased.) In the TC group improvement tended
to occur on 6 of the 7 POMS scales, and the effect was
statistically significant on 4. It should be noted that the
POMS is weighted towards mood items while the BDI
contains many cognitive items.
Table 5 shows results on the visual analogue scales. For
each diagnostic group, on all 8 scales, there was at least a







alone. The one exception occurred in the AT group,
who showed a slight tendency to describe more agitation
after combined treatment. The advantages for combined
treatment were statistically significant in the AT group on
4 scales, in the TC group on 6 scales.
Table 6 shows the statistically significant correlations
between changes in mood and changes in the serum




, and total T
$
.
As shown earlier in Table 2, combined hormone treatment





robust increase in total T
$
. Changes in TSH were slight –
a decrease in the AT group ; an increase in the TC group
– and variances around the means were large. After
combined hormone treatment, TSH changes were as
follows : AT group, 5 decreases, 6 increases ; TC group, 5
decreases, 10 increases. It is important to note that while
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Table 4. Mood changes after treatment with thyroxine (T
%














Autoimmune thyroiditis (n¯ 11)
Beck Depression Inventory 8.5³7.8 8.9³5.8 ns
Spielberger State Anxiety Inventory 41³11 43³7 ns
Profile of mood states
Global score 20³24 18³23 ns
Fatigue–inertia 7.5³4.2 6.9³3.5 ns
Depression–dejection 8.1³6.8 8.6³7.3 ns
Anger–hostility 6.1³5.7 6.1³4.5 ns
Confusion–bewilderment 3.6³3.6 3.5³3.2 ns
Tension–anxiety 7.5³4.8 7.1³5.6 ns
Vigour–activity 13.2³4.5 13.9³4.2 ns
Thyroid cancer (n¯ 15)
Beck Depression Inventory 9.4³7.2 6.3³4.0 ns
Spielberger State Anxiety Inventory 47³10 47³8 ns
Profile of mood states
Global score 36³28 23³24 0.02
Fatigue–inertia 10.1³4.5 7.2³4.1 0.006
Depression–dejection 14.9³9.2 8.8³7.8 0.001
Anger–hostility 9.3³6.2 6.9³5.9 0.03
Confusion–bewilderment 5.7³4.4 4.6³3.2 ns
Tension–anxiety 8.7³6.1 7.7³6.0 ns
Vigour–activity 12.5³4.5 12.3³3.6 ns
few correlations with biochemical variables were found
(Table 6). Changes in TSH serum concentration correlated
positively with 5 changes in mood : when TSH increased,
mood improved ; when TSH decreased, mood worsened,
however slightly. In addition, after combined hormone
treatment, as free T
%
fell, mood improved and two
negative correlations emerged. No correlations between
mood and total T
%
or between mood and total T
$
occurred.







alone (data not shown). This was apparent on 6 of 7
visual analogue scales pertaining to mental and somatic
symptoms (Bunevicius et al., 1999).
Discussion
It appears that the amount of T
$
, however small, normally
secreted by the thyroid gland is necessary for the
maintenance of normal brain function. Patients who more
lacked T
$
secretion, i.e. patients with thyroidectomy for
cancer, profited more from combined treatment than did
patients with residual thyroid function, i.e. patients with
thyroiditis. The substitution of T
$
in approximately
physiological amounts (or slight excess) for a portion of
exogenous T
%
benefited both cognition and mood, two
functions adversely affected by hypothyroidism
(Whybrow et al., 1969). Both performance tests and
subjective ratings supported these observations. The
improvement in mood was greater than the improvement
in cognition.
Two other groups have studied the role of T
$
in
thyroid hormone replacement. Smith et al. (1970) used







alone, presumably because it caused less
toxicity. Cooke et al. (1992) performed an open trial that
involved nine depressed patients receiving T
%
replace-
ment but responding poorly to their antidepressant drugs.
When the authors added T
$
(15–50 µg) to the daily
regimen, a marked decrease in depression occurred in 7
patients.
More recent evidence from both the clinic and the
laboratory suggests that T
$
can play a useful role in
replacement therapy. Van Wassenaer et al. (1998) gave
T
%
to premature human infants. Hypothyroxinaemia was
corrected but the pattern of thyroid hormones caused
the authors to suggest that T
$
might play a useful role
in treatment. Escobar-Morreale et al. (1996) thyroidec-
tomized rats, gave them various doses of T
%
and studied
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Table 5. Results of visual analogue scales after treatment
with thyroxine (T
%
















Sad 32³26 18³16 0.02
Confused 27³21 13³18 0.02
Fearful 30³32 16³20 0.02
Irritable 37³26 26³28 0.02
Tense 33³27 21³20 ns
Angry 29³29 19³20 ns
Tired 45³27 35³32 ns
Agitated 34³29 38³25 ns
Thyroid cancer
(n¯ 15)
Sad 40³20 27³19 0.01
Confused 35³22 24³19 0.03
Fearful 34³31 25³25 0.05
Irritable 41³29 26³20 0.01
Tense 48³30 30³24 0.01
Angry 29³24 24³19 ns
Tired 54³25 45³29 ns
Agitated 47³32 33³30 0.007
Table 6. Statistically significant Pearson’s correlations (r)
between improvements in mood and changes in biochemical
values after combined treatment
∆ Thyrotropin ∆ Free T
%





Thyroid cancer (n¯ 15)






* p! 0.05 ; ** p! 0.01 ; *** p! 0.005.
dose of T
%
that would fully restore tissue concentrations
of T
$
. Cerebral cortex and cerebellum were exceptions to
this finding. These exceptions, pertaining to parts of the
brain, appear to contradict the thrust of the present report.
However, Campos-Barros et al. (1996) have identified
differences between rat brain and human brain in T
$
production.
The results regarding magnitude of change in TSH
concentration by themselves could be taken as reflecting
the importance for mood improvement of simply chang-
ing the existing dynamics of the hypothalamic–
pituitary–thyroid axis. The variability in TSH response to
combined hormone treatment, especially the frequent
increase in TSH concentration, though not expected, is
not without precedent. Ridgway et al. (1979) reported
that T
$
treatment of hypothyroid patients increased TSH
secretion evident in the TRH stimulation test.
There are several ways in which T
$
administration
might improve mental function. Increased serum concen-
trations of T
$
will cause more T
$
to be presented to the
brain, and in brain T
$
, among other functions, may act as
a neurotransmitter (Mason et al., 1993). Furthermore, T
$
alters the dynamics of several classical neurotransmitters
in the brain in such a way as might enhance mood (Mason
et al., 1987a–c). Gur et al. (1999) have recently shown that
T
$
exerts a positive effect on serotonin in the rat frontal
cortex.
The administration of T
$
in patients whose thyroid
gland cannot secrete it will produce a pattern of thyroid
hormones in serum that almost reaches normal. This may





5«DII enzyme is modulated in brain by serum thyroid
hormones (Leonard and Kohrle, 1996). 5«DII activity and
local T
$






itself has only a minor
influence. T
%
also activates its own conversion to reverse
T
$




In the present study a correlate with improved mood
was decreased concentration of T
%
, its free, active moiety.
Whatever the change in TSH, free T
%
decreased in 22 of
26 patients. However, caution must guide the interpret-
ation of the correlations presented in Table 6. Eighteen
mood variables were tested against four biochemical
variables for two diagnostic groups. Only seven stat-
istically significant correlations were found in this matrix
of 144 tests. It may not be chance, however, that caused
all seven significant correlations to pertain to only 2 of the
4 biochemical variables.
If reducing brain concentration of T
%
, whatever its
downstream consequences might be, were the only factor
in causing mood improvement after T
$
administration,
then induced increases of T
%
might be expected to have
untoward mood effects. Here a study of patients with
depression may be germane. Prange et al. (1970) prefaced
standard imipramine treatment of depressed women with
an intramuscular dose of bovine TSH or placebo. The
women who received TSH experienced a doubling in
protein-bound iodine, a measure mainly of total T
%
, in
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antidepressant response. Of course, T
$
concentrations,
which were not then measurable, may also have increased,
because it is now known that when TSH secretion is
suddenly evoked by intravenous administration of thyro-
tropin-releasing hormone, T
$
, as well as T
%
concentration,
is increased even more promptly (Hollander et al., 1972).





, the latter will persist in serum for days,
not hours, due to differences in half-lives.





administration? Joffe and Levitt (1993)
provided a full consideration of this issue. Lithium is an
example of an antithyroid drug with psychotropic effects,
and lithium, like T
$
, has been shown to be an effect-
ive augmentation agent in drug-resistant depression
(Aronson et al., 1996 ; Dufresne, 1996). Although it is an
antithyroid agent, lithium, in fact, may increase T
$
activity
in the brain. Baumgartner et al. (1995) have made this
observation and have related T
$
activation to lithium’s
efficacy in preventing relapse in affective disorders.
Moreover, Bolaris et al. (1995), performing both in vivo
and in vitro studies in rats, demonstrated that lithium
causes an increase in nuclear T
$
binding in brain tissue. In
any case, it should be recalled that the mental symptoms
of hypothyroidism, not those of hyperthyroidism, re-
semble those of depression (Nemeroff and Evans, 1989).
Whatever the solution to the foregoing puzzle, one
might ask why the thyroid gland bothers, as it were, to
secrete any T
$
, however little it may be. There are several
situations in which a shift toward T
$
secretion appears
adaptive : incipient thyroid gland failure (Ingbar, 1985) ;
shortage of dietary iodine (Delange et al., 1972), and
forced overeating (Utiger, 1982). Of course, the shifts in
these conditions may reflect increased deiodination of T
%




Apart from whatever role T
$
may play in stressful
situations, present data suggest it may also play a role in
usual situations. Glandular secretion of T
$
may provide a
base to which other tissues make additions by de-
iodination of T
%
, achieving from this combination of
sources their needed concentration of T
$
. When such base
is deficient, the consequences may be more readily
discerned in the functions of brain than in the functions of
other tissues.
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